Factors affecting the pharmacokinetics of CPT-11: The body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11

Investigational New Drugs

Volumn 19, Issue 1, 2001, Pages 61-67

  Miya, Toshimichi ^a   Goya, Tomoyuki ^a   Fujii, Hirofumi ^b   Ohtsu, Tomoko ^b   Itoh, Kuniaki ^b   Igarashi, Tadahiko ^b   Minami, Hironobu ^b   Sasaki, Yasutsuna ^b  

^a KYORIN UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Dose adjustment; Irinotecan obesity; Pharmacokinetics

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CREATININE; INDOCYANINE GREEN; IRINOTECAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY SURFACE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BODY MASS INDEX; CAMPTOTHECIN; ENZYME INHIBITORS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS; SEX FACTORS;

EID: 0035096162     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006456717846     Document Type: Article

References (28)

1. Clinical pharmacokinetics-pharmacodynamics of anticancer drug
2. Prediction of carboplatin clearance from standard morphological and biological patient characteristics
3. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function
4. Doxorubicin pharmacokinetics: The effect of abnormal liver biochemistry test
5. Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation
6. Pharmacokinetic study of mitomycin C with emphasis on the influence of aging
7. Gender affect doxorubicin pharmacokinetics in patients with normal liver biochemistry
8. The influence of relative body weight on toxicity of combination chemotherapy with cisplatin and etoposide
9. Pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38
10. Nonlinear pharmacokinetics of CPT-11 in rats
11. Metabolism and pharmacokinetics of camptothecin analogue CPT-11 in the mouse
12. A pharmacokinetic analysis program (MULTI) for microcomputer
13. Descriptive epidemiology of body weight and weight change in U.S. adults
14. Estimation of human body surface area from height and weight
15. A formula to estimate the approximate surface area if height and weight be known
16. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man
17. Etoposide pharmacokinetics in patients with normal and abnormal organ functions
18. Creatinine clearance as a predictor of ultrafilterable platinum diposition in cancer patients treated with cisplatin: Relationship between peak ultrafilteracl platinum levels and nephrotoxicity
19. Dose calculation of anticancer drags: A review of the current practice and introduction of an alternative
20. Pharmacokinetics of sufentanil in obese patients
21. Doxorubicin clearance in the obese
22. Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients
23. Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution
24. Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lympoblastic leukemia
25. The influence of aging on cisplatin pharmacokinetics in lung cancer patients with normal organ function
26. Influence of age on the pharmacokinetics of irinotecan (CPT-11) and its metabolites, SN-38 and SN-38 glucuronide (SN-38G), in patients with previously treated colorectal cancer
27. A population pharmacokinetic model for docetaxel: Model building and validation
28. Population pharmacokinetics of docetaxel in Japanese patients